0001493152-16-015280.txt : 20161118
0001493152-16-015280.hdr.sgml : 20161118
20161118171004
ACCESSION NUMBER: 0001493152-16-015280
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160419
FILED AS OF DATE: 20161118
DATE AS OF CHANGE: 20161118
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: GALECTIN THERAPEUTICS INC
CENTRAL INDEX KEY: 0001133416
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043562325
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4960 PEACHTREE INDUSTRIAL BOULEVARD
STREET 2: SUITE 240
CITY: NORCROSS
STATE: GA
ZIP: 30071
BUSINESS PHONE: 678-620-3186
MAIL ADDRESS:
STREET 1: 4960 PEACHTREE INDUSTRIAL BOULEVARD
STREET 2: SUITE 240
CITY: NORCROSS
STATE: GA
ZIP: 30071
FORMER COMPANY:
FORMER CONFORMED NAME: PRO PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20010612
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: CZIRR JAMES C
CENTRAL INDEX KEY: 0001260641
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-31791
FILM NUMBER: 162008513
MAIL ADDRESS:
STREET 1: 425 JANISH DR
CITY: SANDPOINT
STATE: ID
ZIP: 83864
4/A
1
form4a.xml
X0306
4/A
2016-04-19
2016-04-21
0
0001133416
GALECTIN THERAPEUTICS INC
GALT
0001260641
CZIRR JAMES C
C/O GALECTIN THERAPEUTICS, INC. 4960
PEACHTREE INDUSTRIAL BLVD., SUITE 240
NORCROSS
GA
30071
1
0
0
0
Common Stock
2016-04-19
4
S
0
33100
1.6802
D
3271909
I
By 10X Fund, LP
Common Stock
2016-04-20
4
S
0
11212
1.573
D
3260697
I
By 10X Fund, LP
Reflects weighted average price. Range of gross prices were between $1.69 and $1.715. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. This Form 4/A amends the original filing to show the net sales price after deduction of commissions charged by the selling broker.
Reflects weighted average price. Range of gross prices were between $1.55 and $1.62. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. This Form 4/A amends the original filing to show the net sales price after deduction of commissions charged by the selling broker.
The transaction was consummated by 10X Fund, L.P., a Delaware limited partnership, and not by the Reporting Person. The Reporting Person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., and as such, may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. Mr. Czirr disclaims beneficial ownership of the reported securities except to the extent of his after fund payout pecuniary interest therein.
/s/ James C. Czirr
2016-11-18